{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:10:50Z","timestamp":1793437850044,"version":"4.5.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"abstract":"\n Importance<\/jats:title>\n Diagnosing cardiac amyloidosis remains challenging because current imaging approaches are limited to transthyretin amyloidosis. A noninvasive test capable of directly imaging cardiac amyloidosis from various amyloid types and in multiple organs could address an important unmet diagnostic need.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n To evaluate the sensitivity and specificity of\n 124<\/jats:sup>\n I-evuzamitide positron emission tomography (PET)\/computed tomography (CT) for diagnosing cardiac amyloidosis.\n <\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n Prospective, multicenter (18 US centers), single-group study evaluating the efficacy of\n 124<\/jats:sup>\n I-evuzamitide to diagnose cardiac amyloidosis. This study was conducted from January 14, 2025, to March 12, 2026, including a 60-day follow-up period. Three physicians with cardiac PET\/CT experience independently reviewed PET\/CT images for visual cardiac\n 124<\/jats:sup>\n I-evuzamitide uptake while blinded to clinical data. Three expert clinical amyloidosis physicians, blinded to PET\/CT data, independently adjudicated the diagnosis based on the standard-of-care diagnostic algorithm. A total of 195 adults suspected of having cardiac amyloidosis were enrolled when they presented for diagnostic evaluation at participating institutions, excluding patients with an established diagnosis of cardiac or systemic amyloidosis.\n <\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n \n PET\/CT scans were obtained 3 to 5 hours after intravenous administration of 1 mCi of\n 124<\/jats:sup>\n I-evuzamitide. Potassium iodide (130 mg) was given orally for 3 days starting at least 30 minutes prior to\n 124<\/jats:sup>\n I-evuzamitide injection.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n Coprimary end points of this study were to assess the sensitivity and specificity of\n 124<\/jats:sup>\n I-evuzamitide for the diagnosis of cardiac amyloidosis.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Overall, 170 patients were included (median [IQR] age, 72 [64-79] years; 75.3% male, 19.2% Black, 79.0% White). Median N-terminal pro\u2013brain natriuretic peptide was 471 pg\/mL and 61.7% had New York Heart Association class II or III heart failure symptoms. The overall sensitivity was 94% (95% CI, 85%-98%;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001); specificity, 86% (95% CI, 77%-92%;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001); positive predictive value, 85% (95% CI, 75%-92%); and negative predictive value, 94% (95% CI, 87%-98%).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n 124<\/jats:sup>\n I-evuzamitide PET\/CT is highly sensitive and specific for diagnosing cardiac amyloidosis with an acceptable safety profile. These results support\n 124<\/jats:sup>\n I-evuzamitide PET\/CT as a diagnostic test to evaluate patients with suspected cardiac amyloidosis.\n <\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT06788535<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.17361","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T12:30:20Z","timestamp":1788093020000},"source":"Crossref","is-referenced-by-count":3,"title":["124<\/sup>\n I-Evuzamitide Positron Emission Tomography\/Computed Tomography for Diagnosing Cardiac Amyloidosis"],"prefix":"10.1001","author":[{"given":"Sharmila","family":"Dorbala","sequence":"first","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Cardiac Amyloidosis Program, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A. M.","family":"Cuddy","sequence":"additional","affiliation":[{"name":"Cardiac Amyloidosis Program, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar F.","family":"AbouEzzeddine","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo F.","family":"Di Carli","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasken","family":"Dilsizian","sequence":"additional","affiliation":[{"name":"University of Maryland, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesia","family":"Gallegos-Katt\u00e1n","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Guthrie","sequence":"additional","affiliation":[{"name":"Bayer AG, Clinical Development, Radiology, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Mangal","sequence":"additional","affiliation":[{"name":"Solara Consulting Corp, North Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel G.","family":"Khouri","sequence":"additional","affiliation":[{"name":"Duke University Health System, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Cook County Health, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Washington University, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi K.","family":"Narra","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Orlandi","sequence":"additional","affiliation":[{"name":"Orlandi Consulting, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Ruberg","sequence":"additional","affiliation":[{"name":"Boston University, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dia","family":"Smiley","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Florida, Weston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett W.","family":"Sperry","sequence":"additional","affiliation":[{"name":"Saint Luke\u2019s Mid America Heart Institute, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Udelson","sequence":"additional","affiliation":[{"name":"Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Wall","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Tennessee Health Science Center, Knoxville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"REVEAL Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouaz H","family":"Al-Mallah","sequence":"additional","affiliation":[{"name":"for the REVEAL Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M","family":"Alexander","sequence":"additional","affiliation":[{"name":"for the REVEAL Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabahat","family":"Bokhari","sequence":"additional","affiliation":[{"name":"for the REVEAL Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paco E","family":"Bravo","sequence":"additional","affiliation":[{"name":"for the REVEAL Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panithaya","family":"Chareonthaitawee","sequence":"additional","affiliation":[{"name":"for the REVEAL Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip H","family":"Kuo","sequence":"additional","affiliation":[{"name":"for the REVEAL Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley T","family":"O'Neal","sequence":"additional","affiliation":[{"name":"for the REVEAL Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[{"name":"for the REVEAL Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan A,","family":"Whittle","sequence":"additional","affiliation":[{"name":"for the REVEAL Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Auer","sequence":"additional","affiliation":[{"name":"for the REVEAL Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Foley Kijewski","sequence":"additional","affiliation":[{"name":"for the REVEAL Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier F","family":"Clerc","sequence":"additional","affiliation":[{"name":"for the REVEAL Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"issue":"4","key":"joi260103r1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","article-title":"Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee.","volume":"29","author":"Buxbaum","year":"2022","journal-title":"Amyloid"},{"issue":"6","key":"joi260103r2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis.","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"joi260103r3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review.","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"issue":"24","key":"joi260103r4","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMra2304088","article-title":"Systemic light chain amyloidosis.","volume":"390","author":"Sanchorawala","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"joi260103r5","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jaccao.2021.09.001","article-title":"The evolving epidemiology of amyloidosis.","volume":"3","author":"Wechalekar","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"5","key":"joi260103r6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.jacc.2025.11.012","article-title":"Delayed diagnosis of transthyretin amyloid cardiomyopathy in the modern era: seeing the forest through the trees.","volume":"87","author":"Lyle","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"joi260103r7","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","article-title":"How to image cardiac amyloidosis: a practical approach.","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"16","key":"joi260103r8","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"7","key":"joi260103r9","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging.","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"issue":"5","key":"joi260103r10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jacc.2025.09.004","article-title":"Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC Concise Clinical Guidance.","volume":"87","author":"Kittleson","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"joi260103r11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium.","volume":"32","author":"Lousada","year":"2015","journal-title":"Adv Ther"},{"issue":"1","key":"joi260103r12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","article-title":"Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review.","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"Cardiol Ther"},{"issue":"24","key":"joi260103r13","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"11","key":"joi260103r14","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/ehjci\/jeab095","article-title":"99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis.","volume":"22","author":"Quarta","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"joi260103r15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1161\/CIRCULATIONAHA.120.046680","article-title":"Complexities and pitfalls in cardiac amyloidosis.","volume":"142","author":"Cuddy","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"joi260103r16","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.jcmg.2019.10.015","article-title":"Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis.","volume":"13","author":"Musumeci","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"7","key":"joi260103r17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jcmg.2025.01.018","article-title":"Early detection of transthyretin cardiac amyloidosis using 124I-evuzamitide positron emission tomography\/computed tomography.","volume":"18","author":"Smiley","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"joi260103r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nuclcard.2026.102707","article-title":"Assessment of cardiac involvement in rare forms of amyloidosis using PET\/CT with 124I-evuzamitide (124I-p5+14, AT-01).","volume":"60","author":"Clerc","year":"2026","journal-title":"J Nucl Cardiol"},{"issue":"11","key":"joi260103r19","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.jcmg.2023.08.009","article-title":"Cardiac amyloid detection by PET\/CT imaging of iodine (124I) evuzamitide (124I-p5+14): a phase 1\/2 study.","volume":"16","author":"Wall","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"joi260103r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.nuclcard.2025.102451","article-title":"A tale of two tracers - amyloid imaging with investigational radiotracers iodine (124I) evuzamitide and 99mTc-p5+14 (AT-05).","volume":"56","author":"Martin","year":"2026","journal-title":"J Nucl Cardiol"},{"issue":"11","key":"joi260103r21","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","article-title":"Cardiac amyloid quantification using 124I-evuzamitide (124I-P5+14) versus 18F-florbetapir: a pilot PET\/CT study.","volume":"16","author":"Clerc","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"joi260103r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.nuclcard.2026.102773","article-title":"Design and rationale of the REVEAL PET study: a study of (124)I-evuzamitide to diagnose cardiac amyloidosis.","volume":"61","author":"Dorbala","year":"2026","journal-title":"J Nucl Cardiol"},{"issue":"3","key":"joi260103r23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11307-021-01681-2","article-title":"First in human evaluation and dosimetry calculations for peptide 124I-p5+14-a novel radiotracer for the detection of systemic amyloidosis using PET\/CT imaging.","volume":"24","author":"Wall","year":"2022","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"joi260103r24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial.","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"issue":"5","key":"joi260103r25","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.3390\/molecules20057657","article-title":"Preclinical validation of the heparin-reactive peptide p5+14 as a molecular imaging agent for visceral amyloidosis.","volume":"20","author":"Wall","year":"2015","journal-title":"Molecules"},{"issue":"4","key":"joi260103r26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/13506129.2025.2553525","article-title":"A cautionary case series: tafamidis mistreatment following erroneous diagnosis of transthyretin cardiac amyloidosis.","volume":"32","author":"Muchtar","year":"2025","journal-title":"Amyloid"},{"issue":"3","key":"joi260103r27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/13506129.2023.2171787","article-title":"Factors affecting the accuracy of amyloidosis identification and referral to a specialty centre.","volume":"30","author":"Staron","year":"2023","journal-title":"Amyloid"},{"issue":"27","key":"joi260103r28","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"joi260103r29","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"joi260103r30","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.jacc.2025.03.477","article-title":"Impact of heart failure severity on vutrisiran efficacy in transthyretin amyloidosis with cardiomyopathy.","volume":"85","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"joi260103r31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"joi260103r32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis.","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2853272\/jama_dorbala_2026_oi_260103_1787077421.71826.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T12:30:21Z","timestamp":1788093021000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2853272"}},"subtitle":["The REVEAL Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":32,"URL":"https:\/\/doi.org\/10.1001\/jama.2026.17361","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,30]]}}}